The popularity of Sildenafil initially fueled a surge for the drug industry, but recent shifts present a uncertain scenario for those considering a stake. Off-patent alternatives are eroding revenue, and continued https://vinnymoxg167689.is-blog.com/48119207/the-blue-pill-and-pharma-a-precarious-bet